Skip Navigation


JAC Advance Access originally published online on November 28, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/1/135    most recent
dkg016v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paolucci, S.
Right arrow Articles by Gerna, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paolucci, S.
Right arrow Articles by Gerna, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 135-139
© 2003 The British Society for Antimicrobial Chemotherapy

Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients

Stefania Paolucci1, Fausto Baldanti1,2, Maurizio Zavattoni1, Giuditta Comolli1, Nazzarena Labò1, Stefano Menzo3, Massimo Clementi4 and Giuseppe Gerna1,*

1 Servizio di Virologia and 2 Laboratori Sperimentali di Ricerca, IRCCS Policlinico San Matteo, 27100 Pavia; 3 Istituto di Microbiologia, Università di Ancona, Ancona; 4 Università Vita-Salute San Raffaele, IRCCS San Raffaele, Milan, Italy

Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002

Objectives: To compare genotypic and phenotypic HIV-1 drug resistance assays.

Methods: Protease inhibitor (PI) susceptibility was phenotypically analysed in HIV-1 isolates and recombinant viruses expressing proteases from viral isolates. Two genotypic interpretation methods were carried out in parallel.

Results: Entirely concordant resistance levels were shown in 5/10 (50%) highly active anti-retroviral therapy (HAART)-experienced patients, whereas minor discrepancies were observed in the remaining five patients.

Conclusions: The four assays provide comparable results. The recombinant virus phenotypic assay may provide the most accurate evaluation of resistance; however, genotypic interpretation procedures are helpful for daily therapeutic decisions.

* Corresponding author. Tel: +39-0382-502420; Fax: +39-0382-502599; E-mail: g.gerna{at}smatteo.pv.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. Ntemgwa, B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Wainberg
Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 604 - 610.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
B. Rodes, J. Sheldon, C. Toro, V. Jimenez, M. A. Alvarez, and V. Soriano
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy
J. Antimicrob. Chemother., April 1, 2006; 57(4): 709 - 713.
[Abstract] [Full Text] [PDF]

Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
D. A. Katzenstein
Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why?
J Int Assoc Physicians AIDS Care (Chic Ill), October 1, 2003; 2(4): 140 - 146.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.